SEQUA.BR Sequana Medical NV EURONEXT pre-market +11.57% 23 Jan 2026: watch €0.57

SEQUA.BR stock leads pre-market movers after a sharp morning rebound. The share price is trading at €0.57, up 11.57% versus the previous close, on 491,122.00 shares traded so far. The move follows heavy selling over 2025 and a stretched technical backdrop. Investors will watch the upcoming 25 March 2026 earnings date and sector flows in Healthcare on EURONEXT for confirmation of a sustainable recovery.

Pre-market price action: SEQUA.BR stock

Sequana Medical NV (SEQUA.BR) is trading pre-market on EURONEXT at €0.57 after opening €0.52 and a previous close of €0.51. Volume is 491,122.00, above the average of 420,279.00, giving a relative volume of 1.17. The intraday range is €0.52–€0.58 and the one-year range remains €0.51–€2.72. The gap higher today looks like a short-covering rally after recent declines rather than a breakout on fresh commercial news.

Fundamentals and valuation: SEQUA.BR stock

Fundamentals remain challenged. Sequana reports EPS -1.23 and a negative PE of -0.46. Market capitalisation is approximately €41.70M with enterprise value near €75.79M. Balance-sheet metrics show cash per share €0.19, current ratio 0.20, and book value per share -€1.02. Low liquidity and negative earnings keep traditional valuation ratios unhelpful, while high payables (days payable 712.42) underline short-term funding stress.

Technical snapshot and trading levels: SEQUA.BR stock

Technicals show a weak trend but short-term relief. RSI is 40.45, MACD histogram slightly negative, and Bollinger Bands sit €0.51–€0.78. Key support is the year low area near €0.51–€0.52; immediate resistance sits at the 50-day average near €0.64 and the 200-day near €0.94. Momentum indicators (Stochastic %K 13.77) point to oversold rebound territory rather than a fresh uptrend.

Meyka AI grade and consensus: SEQUA.BR stock

Meyka AI rates SEQUA.BR with a score of 64.77 out of 100 (Grade B — HOLD). This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. Note other systems show mixed signals: a company rating dated 22 Jan 2026 gives a C / Sell view, reflecting weak cash metrics and negative DCF inputs. These diverging scores highlight model sensitivity to small cap, loss-making names in Healthcare.

Price forecasts and scenarios: SEQUA.BR stock

Meyka AI’s forecast model projects €1.04 over a 12-month horizon versus the current €0.57, implying an upside of 82.92%. Conservative scenario: €0.80 if volumes and clinical updates improve. Base case: €1.04 with steady commercial traction and orderly financing. Upside: €1.60 if DSR adoption accelerates or if strategic partnerships emerge. Forecasts are model-based projections and not guarantees.

Risks and catalysts to monitor: SEQUA.BR stock

Primary risks are continued cash burn, limited liquidity, and clinical or reimbursement setbacks. Watch the 25 March 2026 earnings announcement for cash runway disclosures and revenue guidance. Catalysts include stronger DSR uptake in heart failure, positive payer discussions in core EU markets, or a financing package. Given the fragile balance sheet, any dilution or debt move will materially affect existing holders.

Final Thoughts

SEQUA.BR stock is a high-volatility small-cap to watch after a pre-market jump to €0.57 on 491,122.00 shares. Short-term moves look driven by technical relief and repositioning after a steep multi-quarter decline. Fundamentals remain stretched: EPS -1.23, current ratio 0.20, and a market cap near €41.70M. Our models offer a 12-month central forecast of €1.04, implying +82.92% upside from the current price, but that assumes orderly financing and stronger sales traction. Traders may treat the bounce as a scalp opportunity while longer-term investors should wait for clearer signs: improved cash flow, better payables dynamics, or regulatory/clinical updates. Meyka AI, an AI-powered market analysis platform, flags both the upside case and the balance-sheet risks. For those tracking SEQUA.BR on EURONEXT, monitor volume, the 25 March 2026 earnings report, and sector flows in Healthcare before increasing exposure.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.